NetScientific plc ('NetScientific' or ‘the Group’)
NetScientific Invests in Next Generation, Immunotherapeutics Company,
PDS Biotechnology
NetScientific (AIM:NSCI), the biomedical and healthcare technology
group, today announced it has made an investment in PDS
Biotechnology Corporation (‘PDS’).
PDS is a clinical stage immunotherapy company developing a
next-generation of simpler, safer and more effective immunotherapies for
cancer and infectious disease. Its novel synthetic nanoparticle platform
technology developed by PDS, Versamune®, activates multiple
immunological mechanisms which direct the targeting of cancer and
infectious disease by the immune system.
The Company’s lead product, PDS0101, is in phase I clinical trials in
the US for HPV-related cancers. PDS has licensed the Versamune®
technology to Merck KGaA for use in two early stage cancer immunotherapy
programmes. The company has also ongoing pre-clinical programmes for
other cancers as well as pandemic influenza.
Farad Azima, CEO, “This is an exceptional opportunity for NetScientific.
As we stated in our recent results, we have been evaluating
opportunities in the therapeutic space. PDS Biotechnology is at the
forefront of cancer immunotherapies and by investing in the company,
represents our entry into next generation therapeutics.”
Sir Richard Sykes, Chairman added, “The groundbreaking work of PDS in
developing immunotherapeutics has the potential to transform treatments
for a wide range of cancers and infectious diseases. We are delighted to
be supporting the Company through its next stage of development.”
-Ends-
Notes to Editors
About NetScientific
NetScientific is a biomedical and healthcare technology group that funds
and develops technologies that offer transformative benefits to people’s
lives and society through improved diagnosis, prognosis and treatment.
For more information, please visit the website at www.NetScientific.net
About PDS
PDS Biotechnology is an immunotherapeutics company developing its
powerful nanoparticle technology, called Versamune®, as a novel cancer
therapy platform with outstanding potential in directing the immune
system to recognise and fight disease. The Company is developing a range
of applications in cancer and infectious disease and its first lead
compound is in phase I clinical trials. The company is based in New
Jersey, US. For specific information on PDS please contact Michael King
at mking@pdsbiotech.com. http://www.pdsbiotech.com
Copyright Business Wire 2014